Protavio completes the latest GMP production of Luminex serological assays for vaccine assessment and QC

Image 20240618 173755 265 redacted

Protavio has finished the latest GMP production of the custom Luminex serological assays for vaccine assessment and Quality Control (QC).

These Luminex® Serological Assays are essential tools for the QC and batch release of new vaccines by pharmaceutical companies. They play a critical role in quantifying antibodies post-vaccination, ensuring that new vaccines meet the necessary standards for efficacy before reaching the market.
Protavio’s Good Manufacturing Practices (GMP) ensures our assays are produced to the highest standards of quality. This rigorous process guarantees that every batch of assays is consistent, reliable, and meets stringent quality requirements.

At Protavio, we are committed to advancing proteomics and supporting the global healthcare community with state-of-the-art Luminex assays. We are extremely honored to be involved in the production of Luminex assays that are being used to ensure the efficacy of pediatric vaccines.

Scroll to Top